What is the effect of the inherited (familial) mutations in SCN9A on the function of NaV1.7, in
the condition of Congenital Insensitivity to Pain? Further, What is it about where NaV1.7 is expressed in the CNS and PNS, and its normal physiological function(s), that make it such an attractive target for the many pharmaceutical and biotech companies attempting to develop drugs that target NaV1.7?
This disfunction seems to have three pain disorders. It has been known to cause primary erythermalgia and paroxysmal extreme... View the full answer